These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 38243263)
21. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2. Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y Front Immunol; 2023; 14():1155182. PubMed ID: 37275857 [TBL] [Abstract][Full Text] [Related]
22. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers. Wang N; Zhu L; Wang L; Shen Z; Huang X Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736 [TBL] [Abstract][Full Text] [Related]
23. Prognosis and immune infiltration analysis of endoplasmic reticulum stress-related genes in bladder urothelial carcinoma. Wang Y; Zhu H; Wang X Front Genet; 2022; 13():965100. PubMed ID: 36186448 [No Abstract] [Full Text] [Related]
24. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker. Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W Front Immunol; 2021; 12():646523. PubMed ID: 33679809 [TBL] [Abstract][Full Text] [Related]
25. Comprehensive Analysis of Liu J; Zhu B; Chen J; Cao Y Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558 [TBL] [Abstract][Full Text] [Related]
26. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation. Qin Y; Yang J; Liang C; Liu J; Deng Z; Yan B; Fu Y; Luo Y; Li X; Wei X; Li W Front Immunol; 2022; 13():994828. PubMed ID: 36405728 [TBL] [Abstract][Full Text] [Related]
27. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma. Huang S; Sun L; Hou P; Liu K; Wu J Front Immunol; 2022; 13():944898. PubMed ID: 36148220 [TBL] [Abstract][Full Text] [Related]
28. Pan-Cancer Analysis of the Oncogenic and Immunological Role of Ding J; Meng Y; Han Z; Luo X; Guo X; Li Y; Liu S; Zhuang K Front Oncol; 2022; 12():811567. PubMed ID: 35651805 [TBL] [Abstract][Full Text] [Related]
29. FAIM2 is a potential pan-cancer biomarker for prognosis and immune infiltration. Cai J; Ye Z; Hu Y; Wang Y; Ye L; Gao L; Sun Q; Tong S; Sun Z; Yang J; Chen Q Front Oncol; 2022; 12():998336. PubMed ID: 36185230 [TBL] [Abstract][Full Text] [Related]
30. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy. Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048 [TBL] [Abstract][Full Text] [Related]
31. Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker. Liu W; Liu C; You J; Chen Z; Qian C; Lin W; Yu L; Ye L; Zhao L; Zhou R Front Cell Dev Biol; 2022; 10():954214. PubMed ID: 36120577 [No Abstract] [Full Text] [Related]
32. Pan-Cancer and Single-Cell Analysis Reveals CENPL as a Cancer Prognosis and Immune Infiltration-Related Biomarker. Feng Z; Chen Y; Cai C; Tan J; Liu P; Chen Y; Shen H; Zeng S; Han Y Front Immunol; 2022; 13():916594. PubMed ID: 35844598 [TBL] [Abstract][Full Text] [Related]
33. Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816 [No Abstract] [Full Text] [Related]
34. Heat Shock Protein 90 Family Isoforms as Prognostic Biomarkers and Their Correlations with Immune Infiltration in Breast Cancer. Lin T; Qiu Y; Peng W; Peng L Biomed Res Int; 2020; 2020():2148253. PubMed ID: 33145341 [TBL] [Abstract][Full Text] [Related]
35. CCL5 might be a prognostic biomarker and associated with immuno-therapeutic efficacy in cancers: A pan-cancer analysis. Huang Y; Wu L; Sun Y; Li J; Mao N; Yang Y; Zhao M; Ren S Heliyon; 2023 Jul; 9(7):e18215. PubMed ID: 37519664 [TBL] [Abstract][Full Text] [Related]
36. Pan-Cancer analysis shows that ACO2 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including hepatocellular carcinoma. Wang Z; Zheng W; Chen Z; Wu S; Chang H; Cai M; Cai H Front Oncol; 2022; 12():1055376. PubMed ID: 36531056 [TBL] [Abstract][Full Text] [Related]
37. A comprehensively prognostic and immunological analysis of chloride intracellular channel protein 5 (CLIC5) in pan-cancer and identification in ovarian cancer. Huang Q; Lv Q; Tang W; Pan Y; Xing Y; He M; Wu H; Huang J; Huang C; Lan H; Chen J; Xiao G J Cancer Res Clin Oncol; 2023 Sep; 149(12):10561-10583. PubMed ID: 37286734 [TBL] [Abstract][Full Text] [Related]
38. A multidimensional pan-cancer analysis of DCAF13 and its protumorigenic effect in lung adenocarcinoma. Wei S; Lu K; Xing J; Yu W FASEB J; 2023 Apr; 37(4):e22849. PubMed ID: 36884358 [TBL] [Abstract][Full Text] [Related]
39. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker. Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933 [TBL] [Abstract][Full Text] [Related]
40. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy. Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]